Anti-PD-1 Drugs Vie for Urothelial Cancer Indication (CME/CE)

(MedPage Today) -- Pembrolizumab active in cisplatin-ineligible disease, nivolumab in recurrence
via Anti-PD-1 Drugs Vie for Urothelial Cancer Indication (CME/CE)
by